Ignite Creation Date:
2024-05-05 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00299286
Status:
COMPLETED
Last Update Posted:
2012-08-06
First Post:
2006-03-03
Brief Title:
Short-term Presurgical Study to Assess Molecular Predictors of Lapatinibs Effects in Primary Breast Cancer
Sponsor:
Institute of Cancer Research United Kingdom
Organization:
Institute of Cancer Research United Kingdom
Study Overview
Official Title:
A Double Blind Short-Term Presurgical Study Assessing the Molecular Antiproliferative Predictors of Lapatinibs Effects in Breast Cancer
Status:
COMPLETED
Status Verified Date:
2012-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MAPLE
Brief Summary:
To provide an in vivo measure of the activity of lapatinib To assess the antiproliferative effects of lapatinib in breast cancer ie how much lapatinib slows down the growth of cancer cells by measuring K167 a marker of proliferation in breast tumours before and after a short treatment with lapatinib
Detailed Description:
Randomised multi centre double blind pre-surgical study in women with a histological diagnosis of breast cancer by core biopsy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None